ReviewQuantitative imaging in medicine and surgery2026
Mediastinal adipose tissue as an active player in cardiovascular disease: a multimodality imaging narrative review.
Review in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Mediastinal adipose tissue comprises several distinct fat depots, including epicardial, pericoronary, pericardial, and paracardial adipose tissue, which surround the heart and great vessels and actively contribute to cardiovascular pathophysiology. Under physiological conditions, these adipose compartments exert protective metabolic and mechanical functions; however, in pathological states, their expansion and remodeling promote inflammation, endothelial dysfunction, fibrosis, and atherosclerotic progression. This narrative review aims to summarize the current evidence regarding the anatomical distribution, imaging assessment, and clinical implications of mediastinal adipose tissue in cardiovascular disease. Methods: A narrative review was conducted using PubMed, Scopus, and Web of Science databases, covering publications up to January 2026. Only articles published in English were considered. Original research articles and relevant reviews focusing on imaging, pathophysiology, and clinical implications of mediastinal adipose tissue were included. Reference lists of selected studies were additionally screened to identify additional relevant publications. Key Content and Findings: Computed tomography (CT) enables highly reproducible volumetric and qualitative assessment of cardiac adipose tissue, including inflammatory markers such as the fat attenuation index (FAI). Magnetic resonance imaging (MRI) provides excellent tissue characterization without ionizing radiation, whereas echocardiography represents a simple and widely available screening tool. Increased epicardial, pericoronary, and pericardial adipose tissue (PAT) burden has been consistently associated with coronary artery disease (CAD), atrial fibrillation (AF), and heart failure (HF), particularly HF with preserved ejection fraction (HFpEF). Emerging evidence also supports the potential role of artificial intelligence (AI) and radiomics for automated quantification and cardiovascular risk stratification. Conclusions: Mediastinal adipose tissue is increasingly recognized as an active biomarker and potential therapeutic target in cardiovascular disease. Multimodality imaging plays a central role in its evaluation by providing complementary anatomical, functional, and inflammatory information. Further standardization of imaging methodologies and validation of treatment-related changes are needed to support future clinical applications and personalized cardiovascular risk assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.